What Made H.C. Wainwright Downgrade Fibrocell Science Inc’s Stock?


Fibrocell Science Inc (FCSC) received a Hold rating and a $3 price target from H.C. Wainwright analyst Joseph Pantginis today. The company’s shares closed last Monday at $2.93.

Pantginis commented:

“Valuation and risks to price target achievement. We are downgrading to Neutral and lowering our price target to $3 from $20 to reflect the valuation offered and accepted by Fibrocell’s management as part of the acquisition terms. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Further, until closing, there is no guarantee that the acquisition will close, which could then prompt us to reassess our valuation of Fibrocell.”

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -9.3% and a 33.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Fibrocell Science Inc is a Hold with an average price target of $3.

See today’s analyst top recommended stocks >>

Based on Fibrocell Science Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $11.74 million. In comparison, last year the company had a GAAP net loss of $2.89 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts